Entinostat

Profil Farmakokinetik

Waktu Paruh (Half-Life) -

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

405 Data

Ivabradine	Ivabradine may increase the QTc-prolonging activities of Entinostat.
Vorinostat	The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Entinostat is combined with Vorinostat.
Dofetilide	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Dofetilide.
Citalopram	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Citalopram.
Anagrelide	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Anagrelide.
Disopyramide	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Disopyramide.
Clemastine	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Clemastine.
Ibutilide	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Ibutilide.
Valproic acid	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Valproic acid.
Terfenadine	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Terfenadine.
Grepafloxacin	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Grepafloxacin.
Quinine	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Quinine.
Sotalol	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Sotalol.
Erlotinib	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Erlotinib.
Toremifene	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Toremifene.
Cisapride	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Cisapride.
Imatinib	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Imatinib.
Astemizole	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Astemizole.
Thioridazine	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Thioridazine.
Trovafloxacin	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Trovafloxacin.
Mifepristone	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Mifepristone.
Cocaine	The risk or severity of methemoglobinemia can be increased when Entinostat is combined with Cocaine.
Quinidine	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Quinidine.
Procainamide	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Procainamide.
Pimozide	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Pimozide.
Amiodarone	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Amiodarone.
Arsenic trioxide	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Arsenic trioxide.
Escitalopram	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Escitalopram.
Domperidone	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Domperidone.
Sparfloxacin	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Sparfloxacin.
Halofantrine	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Halofantrine.
Bepridil	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Bepridil.
Paliperidone	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Paliperidone.
Lithium cation	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Lithium cation.
Temafloxacin	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Temafloxacin.
Zuclopenthixol	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Zuclopenthixol.
Tetrabenazine	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Tetrabenazine.
Dronedarone	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Dronedarone.
Nilotinib	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Nilotinib.
Iloperidone	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Iloperidone.
Vandetanib	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Vandetanib.
Romidepsin	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Romidepsin.
Asenapine	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Asenapine.
Artemether	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Artemether.
Lumefantrine	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Lumefantrine.
Vemurafenib	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Vemurafenib.
Eliglustat	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Eliglustat.
Ribociclib	The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Entinostat.
Glasdegib	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Glasdegib.
Deutetrabenazine	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Deutetrabenazine.
Macimorelin	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Macimorelin.
Terodiline	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Terodiline.
Leuprolide	The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Entinostat.
Goserelin	The risk or severity of QTc prolongation can be increased when Goserelin is combined with Entinostat.
Erythromycin	The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Entinostat.
Azithromycin	The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Entinostat.
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Entinostat.
Ranolazine	The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Entinostat.
Sulfisoxazole	The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Entinostat.
Amitriptyline	The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Entinostat.
Methadone	The risk or severity of QTc prolongation can be increased when Methadone is combined with Entinostat.
Diltiazem	The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Entinostat.
Clozapine	The risk or severity of QTc prolongation can be increased when Entinostat is combined with Clozapine.
Sulpiride	The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Entinostat.
Nimodipine	The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Entinostat.
Promazine	The risk or severity of QTc prolongation can be increased when Promazine is combined with Entinostat.
Prochlorperazine	The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Entinostat.
Droperidol	The risk or severity of QTc prolongation can be increased when Droperidol is combined with Entinostat.
Imipramine	The risk or severity of QTc prolongation can be increased when Imipramine is combined with Entinostat.
Chlorpromazine	The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Entinostat.
Oxaliplatin	The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Entinostat.
Ciprofloxacin	The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Entinostat.
Fluorouracil	The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Entinostat.
Perflutren	The risk or severity of QTc prolongation can be increased when Perflutren is combined with Entinostat.
Cinnarizine	The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Entinostat.
Atropine	The risk or severity of QTc prolongation can be increased when Atropine is combined with Entinostat.
Chloroquine	The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Entinostat.
Efavirenz	The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Entinostat.
Adenosine	The risk or severity of QTc prolongation can be increased when Adenosine is combined with Entinostat.
Pentamidine	The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Entinostat.
Gadobenic acid	The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Entinostat.
Carbinoxamine	The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Entinostat.
Dolasetron	The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Entinostat.
Roxithromycin	The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Entinostat.
Nalidixic acid	The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Entinostat.
Cinoxacin	The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Entinostat.
Loperamide	The risk or severity of QTc prolongation can be increased when Loperamide is combined with Entinostat.
Granisetron	The risk or severity of QTc prolongation can be increased when Granisetron is combined with Entinostat.
Ondansetron	The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Entinostat.
Levosimendan	The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Entinostat.
Mesoridazine	The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Entinostat.
Desloratadine	The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Entinostat.
Telithromycin	The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Entinostat.
Lomefloxacin	The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Entinostat.
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Entinostat.
Primaquine	The risk or severity of QTc prolongation can be increased when Primaquine is combined with Entinostat.
Papaverine	The risk or severity of QTc prolongation can be increased when Papaverine is combined with Entinostat.
Chlorpheniramine	The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Entinostat.
Nifedipine	The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Entinostat.
Levofloxacin	The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Entinostat.

Target Protein

Histone deacetylase HDAC1

Histone deacetylase 1 HDAC1

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0

Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual